Lipid-lowering Drug Summary
1
Drug Class Indicat ion Drug effect MOA Side Effects Drug Interactions Pharmacologi c Vitamin (=Niacin) HDL TG, VLDL synth, adipocyte lipolysis, HDL 25- 30%, LDL Hepatic synthesis of TG & VLDL, conversion of VLDL to LDL Vasodilation, cutaneous flushing Hyperglycemia/ acanthosis nigrans, Hyperuricemia/ gout flare May require anti-HTN meds, anti-DM meds Bile-acid binding resin (e.g. cholestyrami ne, colestipol) LDL (and nl /low TG) LDL, TG Binds bile acid absorption in intestine. Malabsorption, cholelithiasis , Impaired absorption drugs/nutrient s, worsened diverticulosis 2/2 constipation Malabsorption— administer 4 hrs apart from statins Fibrates (e.g. gemfibrozil) : TG TG, VLDL, lipoprote in lipase activity Activates PPAR-alpha. Inhibits cholesterol 7a- hydroxylase Cholesterol gallstones, myopathy Cholelithiasis . If combined w/ statins: myopathy Cholesterol absorption blocker (e.g. Ezetimibe LDL 30% in serum LDL. intestinal abs. of CL LFTs, myopathy (rare) Use w/ statins Statins LDL hep cholestero l synthesis, LDL-R Inhibits HMG CoA Reductase Myopathy & hepatitis, risk if co- administered w/ CYP inhibitor. Except pravastatin. Metabolized by CYP 3A4, so watch out for CYP modifiers!
description
Lipid-lowering Drug Summary
Transcript of Lipid-lowering Drug Summary
Drug ClassIndicationDrug effectMOASide EffectsDrug Interactions
Pharmacologic Vitamin (=Niacin) HDL TG, VLDL synth, adipocyte lipolysis, HDL 25-30%, LDLHepatic synthesis of TG & VLDL, conversion of VLDL to LDL Vasodilation, cutaneous flushing Hyperglycemia/ acanthosis nigrans, Hyperuricemia/ gout flareMay require anti-HTN meds, anti-DM meds
Bile-acid binding resin (e.g. cholestyramine, colestipol) LDL (and nl /low TG)LDL, TG Binds bile acid absorption in intestine. Malabsorption, cholelithiasis, Impaired absorption drugs/nutrients, worsened diverticulosis 2/2 constipation Malabsorptionadminister 4 hrs apart from statins
Fibrates (e.g. gemfibrozil): TG TG, VLDL, lipoprotein lipase activity Activates PPAR-alpha. Inhibits cholesterol 7a-hydroxylase Cholesterol gallstones, myopathyCholelithiasis. If combined w/ statins: myopathy
Cholesterol absorption blocker (e.g. EzetimibeLDL30% in serum LDL. intestinal abs. of CLLFTs, myopathy (rare)Use w/ statins
Statins LDL hep cholesterol synthesis, LDL-R Inhibits HMG CoA Reductase Myopathy & hepatitis, risk if co-administered w/ CYP inhibitor. Except pravastatin. Metabolized by CYP 3A4, so watch out for CYP modifiers!
